Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_assertion type Assertion NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_head.
- NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_assertion description "[The frequency of heterozygotes for the 20210A prothrombin allele was 6.5% among patients and 2.8% among controls (OR 2.4, 95% CI 1.0-5.9), increasing to 8.7% in patients with a family history of myocardial infarction (OR 3.3, 95% CI 1.2-9.1), to 9.9% in patients (n=81) with < or =1 vessel disease (OR 3.8, 95% CI 1.3-10.8), and to 13.0% in patients who were normocholesterolaemic, non-diabetic, normotensive and non-smokers (OR 5.1, 95% CI 1.2-21.4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_provenance.
- NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_assertion evidence source_evidence_literature NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_provenance.
- NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_assertion SIO_000772 11741359 NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_provenance.
- NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_assertion wasDerivedFrom befree-20140225 NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_provenance.
- NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_assertion wasGeneratedBy ECO_0000203 NP631707.RAy5zhjI3xQBQDz3sNk4wRqObsocYE1b7oxJu3Rz-NsSE130_provenance.